Latest Life Sciences News

AdAlta Limited has made significant progress in its 'East to West' cellular immunotherapy strategy, advancing licensing negotiations for its first CAR-T product and raising $1.6 million through placements to bolster its financial position.

AnteoTech Ltd reports strong quarterly progress with a key US joint development agreement, significant manufacturing scale-up, and expanded market access in South Korea, underpinning its 2025 commercialisation strategy.

AdAlta Limited has fully repaid its remaining NLSC investment in cash, ending its obligation to issue further shares and positioning itself for private capital raises to advance its CAR-T therapies.

Vitrafy Life Sciences has delivered its first production unit of the next-generation cryopreservation device, advanced its US commercial footprint, and maintained a strong financial position heading into FY2026.

Wellnex Life Limited announces the resignation of CEO Zack Bozinovski, who will remain with the company until April 2026, while a $2.3 million loan repayment schedule is negotiated.

Invion Limited has partnered with Protect Animal Health to explore Photosoft™, a novel photodynamic therapy, as a treatment for cancer in companion animals, targeting a booming pet cancer market.

Cryosite Limited reports a strong start to FY26 with a 22% revenue increase and a strategic warehouse acquisition that doubles capacity, positioning the company for sustained growth in clinical trial logistics.

Invion Limited has secured $0.8 million through convertible notes to repay its Lind Global Fund II LP facility and support working capital, positioning itself for potential global licensing deals of its Photosoft technology.

Pathkey.AI’s TrialKey platform continues to validate its AI-driven clinical trial success predictions, with September 2025 seeing an average 43.6% share price increase across flagged biotech stocks.

Pathkey.AI has upgraded its TrialKey platform to include drug-level molecular and pharmacokinetic features, enhancing clinical trial predictions and opening doors to AI-driven drug discovery.

Bioxyne Limited has secured import permits and purchase orders worth A$5.1 million for medical cannabis in Germany, signaling strong early traction in a key European market.

Vection Technologies has expanded its AI contract portfolio by securing an additional $2.1 million through a deepened exclusive partnership with Area12 Consulting, bringing total contracts since May 2025 to $5.7 million.